Treatment of non-small cell lung cancer: Advanced (metastatic) disease. Guidelines of clinical practice made by the European Lung Cancer Working Party;Traitement des cancers bronchiques non à petites cellules: Maladies avancées (métastatiques). Les recommandations de pratique clinique de l'European Lung Cancer Working Party

Revue Medicale de Bruxelles

Volumn 28, Issue 6, 2007, Pages 495-511

  Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Guidelines; Non small cell lung cancer; Recommendations

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; TOPOTECAN; VINBLASTINE; VINDESINE; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUROPE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALVAGE THERAPY; TREATMENT PLANNING;

EID: 37649006364     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de l'European Lung Cancer working Party. Rev Med Brux 2006 ; 27 : 29-38
2. Management of resectable non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party. Rev Med Brux 2006 ; 27 : 29-38
3. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines : the AGREE project. Qual Saf Health Care 2003 ; 12 : 18-23
4. Burgers JS, Fervers B, Haugh M et al. : International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004 ; 22 : 2000-7
5. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997 ; 15 : 2996-3018
6. Pfister DG, Johnson DH, Azzoli CG et al. : American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline : update 2003. J Clin Oncol 2004 ; 22 : 330-53
7. BTS guidelines : guidelines on the selection of patients with lung cancer for surgery. Thorax 2001 ; 56 : 89-108
8. Levine M, Browman G, Newman T, Cowan DH : The Ontario Cancer Treatment Practice Guidelines Initiative. Oncology (Huntingt) 1996 ; 10 (Suppl 11) : 19-22
9. The Royal College of Radiologists Clinical Oncology Information Network : Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol) 1999 ; 11 : S1-S53
10. Alberts WM : Lung Cancer Guidelines. Introduction. Chest 2003 ; 123 : 1S-2S
11. Depierre A, Lagrange JL, Theobald S et al. : Standards, options et recommandations 2000 pour la prise en charge des patients atteints d'un cancer bronchopulmonaire non à petites cellules (rapport abrégé). Bull Cancer 2003 ; 90 : 151-66
12. McCrory DC, Colice GL, Lewis SZ, Alberts WM, Parker S : Overview of methodology for lung cancer evidence review and guideline development. Chest 2003 ; 123 (Suppl 1) : 3S-6S
13. Cormier Y, Bergeron D, La Forge J et al. : Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 1982 ; 50 : 845-9
14. Rapp E, Pater JL, Willan A et al. : Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer : report of a Canadian multicenter randomized trial. J Clin Oncol 1988 ; 6 : 633-41
15. Ganz PA, Figlin RA, Haskell CM, La Soto N, Siau J : Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference ? Cancer 1989 ; 63 : 1271-8
16. Woods RL, Williams CJ, Levi J et al. : A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 1990 ; 61 : 608-11
17. Kaasa S, Lund E, Thorud E, Hatlevoll R, Host H : Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991 ; 67 : 2443-7
18. Quoix E, Dietemann A, Charbonneau J et al. : La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV ? Résultats d'une étude randomisée. Bull Cancer 1991 ; 78 : 341-6
19. Cellerino R, Tummarello D, Guidi F et al. : A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991 ; 9 : 1453-61
20. Leung WT, Shiu WC, Pang JC et al. : Combined chemotherapy and radiotherapy versus best supportive care in the treatment of inoperable non-small-cell lung cancer. Oncology 1992 ; 49 : 321-6
21. Cartei G, Cartei F, Cantone A et al. : Cisplatin-cyclophosphamide- mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer [see comments]. J Natl Cancer Inst 1993 ; 85 : 794-800
22. Helsing M, Bergman B, Thaning L, Hero U : Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998 ; 34 : 1036-44
23. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J : Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer : best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999 ; 24 : 17-24
24. Cullen MH, Billingham LJ, Woodroffe CM et al. : Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer : Effects on Survival and Quality of Life. J Clin Oncol 1999 ; 17 : 3188-94
25. Spiro SG, Rudd RM, Souhami RL et al. : Chemotherapy versus supportive care in advanced non-small cell lung cancer : improved survival without detriment to quality of life. Thorax 2004 ; 59 : 828-36
26. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999 ; 91 : 66-72
27. Ranson M, Davidson N, Nicolson M et al. : Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer. J Natl Cancer Inst 2000 ; 92 : 1074-80
28. Anderson H, Hopwood P, Stephens RJ et al. : Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer : a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000 ; 83 : 447-53
29. Roszkowski K, Pluzanska A, Krzakowski M et al. : A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) [In Process Citation]. Lung Cancer 2000 ; 27 : 145-57
30. Souquet PJ, Chauvin F, Boissel JP et al. : Polychemotherapy in advanced non small cell lung cancer : a meta-analysis. Lancet 1993 ; 342 : 19-21
31. Grilli R, Oxman AD, Julian JA : Chemotherapy for advanced non-small-cell lung cancer : how much benefit is enough ? J Clin Oncol 1993 ; 11 : 1866-72
32. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F : Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994 ; 106 : 861-5
33. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer : a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 ; 311 : 899-909
34. Sculier JP, Berghmans T, Castaigne A et al. : Best supportive care or chemotherapy for stage IV non small cell lung cancer. In : Van Houtte P, Klastersky J, Rocmans P, eds. Progress and perspectives in lung cancer. Berlin, Springer-Verlag, 1999 : 199-207
35. Socinski MA, Morris DE, Masters GA, Lilenbaum R : Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003 ; 123 (Suppl 1) : 226S-43S
36. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E : Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990 ; 8 : 1301-9
37. Donnadieu N, Paesmans M, Sculier JP : Chimiothérapie des cancers bronchiques non à petites cellules. Méta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Respir 1991 ; 8 : 197-204
38. Meert AP, Berghmans T, Branle F et al. : Phase II and III studies with new drugs for non-small cell lung cancer : a systematic review of the literature with a methodology quality assessment. Anticancer Res 1999 ; 19 (5C) : 4379-90
39. Sculier JP : Treatment of thoracic malignancy - results of meta-analyses. Rev Mal Respir 2005 ; 22 (6 Pt 2) : 8S81-9
40. Marino P, Preatoni A, Cantoni A, Buccheri G : Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer : a quality and meta-analysis study. Lung Cancer 1995 ; 13 : 1-12
41. Lilenbaum RC, Langenberg P, Dickersin K : Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma : a meta-analysis of response, toxicity, and survival. Cancer 1998 ; 82 : 116-26
42. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP : Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer : a meta-analysis. JAMA 2004 ; 292 : 470-84
43. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M : Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer : a literature based meta-analysis of randomised trials. Ann Oncol 2004 ; 15 : 1782-9
44. Sculier JP, Ghisdal L, Berghmans T et al. : The role of mitomycin in the treatment of non-small cell lung cancer : a systematic review with meta-analysis of the literature. Br J Cancer 2001 ; 84 : 1150-5
45. Le Chevalier T, Scagliotti G, Natale R et al. : Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer : a meta-analysis of survival outcomes. Lung Cancer 2005 ; 47 : 69-80
46. Sanchez LB, Penuelas S, I, Guillen GF : Docetaxel en combinacion con cisplatino para el tratamiento en primera linea del cancer del pulmon no microcitico metastasico o localmente avanzado : metaanalisis de ensayos clinicos aleatorizados y controlados. Med Clin (Barc ) 2004 ; 122 : 281-7
47. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK : Taxanes as first-line therapy for advanced non-small cell lung cancer : a systematic review and practice guideline. Lung Cancer 2005 ; 50 : 355-74
48. Crino L, Scagliotti GV, Ricci S et al. : Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer : A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999 ; 17 : 3522-30
49. Gebbia V, Galetta D, Riccardi F et al. : Norelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma : a prospective randomized study. Lung Cancer 2002 ; 37 : 179-87
50. Sculier JP, Lafitte JJ, Lecomte J et al. : A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002 ; 13 : 874-82
51. Negoro S, Masuda N, Takada Y et al. : Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003 ; 88 : 335-41
52. Kubota K, Watanabe K, Kunitoh H et al. : Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer : the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004 ; 22 : 254-61
53. Booton R, Lorigan P, Anderson H et al. : A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer : a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006 ; 17 : 1111-9
54. Crino L, Tonato M, Darwish S et al. : A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC) : a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990 ; 26 : 52-6
55. Gralla RJ, Casper ES, Kelsen DP et al. : Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung : A randomized trial investigating two dosage schedules. Ann Intern Med 1981 ; 95 : 414-20
56. Klastersky J, Sculier JP, Ravez P et al. : A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986 ; 4 : 1780-6
57. Shinkai T, Saijo N, Eguchi K et al. : Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer : a randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986 ; 77 : 782-9
58. Gandara DR, Crowley J, Livingston RB et al. : Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer : a phase III study of the Southwest Oncology Group. J Clin Oncol 1993 ; 11 : 873-8
59. Sculier JP, Lafitte JJ, Paesmans M et al. : Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000 ; 83 : 1128-35
60. Sculier JP, Klastersky J, Giner V et al. : Phase II randomized trial comparing high-dose cisplatin with moderate dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1994 ; 12 : 353-9
61. Klastersky J, Sculier JP, Lacroix H et al. : A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer : European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990 ; 8 : 1556-62
62. Comella P, Scoppa G, Daponte A et al. : Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. Cancer 1994 ; 74 : 1874-81
63. Jelic S, Mitrovic L, Radosavljevic D et al. : Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma : a randomized phase III study. Lung Cancer 2001 ; 34 : 1-13
64. Schiller JH, Harrington D, Belani CP et al. : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 ; 346 : 92-8
65. Rosell R, Gatzemeier U, Betticher DC et al. : Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer : a cooperative multinational trial. Ann Oncol 2002 ; 13 : 1539-49
66. Mazzanti P, Massacesi C, Rocchi MB et al. : Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003 ; 41 : 81-9
67. Fossella F, Pereira JR, von Pawel J et al. : Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer : the TAX 326 study group. J Clin Oncol 2003 ; 21 : 3016-24
68. Zatloukal P, Petruzelka L, Zemanova M et al. : Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer : a phase III randomized trial. Lung Cancer 2003 ; 41 : 321-31
69. Paccagnella A, Favaretto A, Oniga F et al. : Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004 ; 43 : 83-91
70. Chen YM, Perng RP, Tsai CM, Whang-Peng J : A phase II study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. J Thorac Oncol 2006 ; 1 : 141-5
71. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M : Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 3852-9
72. Smith IE, O'Brien ME, Talbot DC et al. : Duration of chemotherapy in advanced non-small-cell lung cancer : a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001 ; 19 : 1336-43
73. Socinski MA, Schell MJ, Peterman A et al. : Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer. J Clin Oncol 2002 ; 20 : 1335-43
74. Belani CP, Barstis J, Perry MC et al. : Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003 ; 21 : 2933-9
75. Westeel V, Quoix E, Moro-Sibilot D et al. : Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005 ; 97 : 499-506
76. von PC, Bergman B, Andresen O et al. : Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006 ; 95 : 966-73
77. Belani CP, Barstis J, Perry MC et al. : Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003 ; 21 : 2933-9
78. von PC, Bergman B, Andresen O et al. : Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006 ; 95 : 966-73
79. Georgoulias V, Papadakis E, Alexopoulos A et al. : Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer : a randomised multicentre trial. Lancet 2001 ; 357 : 1478-84
80. Kosmidis P, Mylonakis N, Nicolaides C et al. : Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer : a phase III randomized trial. J Clin Oncol 2002 ; 20 : 3578-85
81. Greco FA, Gray JR, Jr, Thompson DS et al. : Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma : a minnie pearl cancer research network trial. Cancer 2002 ; 95 : 1279-85
82. Chen YM, Perng RP, Lee YC et al. : Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective : a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 2002 ; 13 : 108-15
83. Gebbia V, Galetta D, Caruso M et al. : Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma : a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003 ; 39 : 179-89
84. Gridelli C, Gallo C, Shepherd FA et al. : Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer : a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003 ; 21 : 3025-34
85. Alberola V, Camps C, Provencio M et al. : Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer : a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003 ; 21 : 3207-13
86. Smit EF, van Meerbeeck JP, Lianes P et al. : Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer : a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group. EORTC 08975. J Clin Oncol 2003 ; 21 : 3909-17
87. Wachters FM, Van Putten JW, Kramer H et al. : First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer : a phase III trial. Br J Cancer 2003 ; 89 : 1192-9
88. Yamamoto N, Fukuoka M, Negoro SI et al. : Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer : a West Japan Thoracic Oncology Group Study (WJTOG9803). Br J Cancer 2004 ; 90 : 87-92
89. Laack E, Dickgreber N, Muller T et al. : Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer : from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004 ; 22 : 2348-56
90. Stathopoulos GP, Veslemes M, Georgatou N et al. : Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer : a randomized phase III trial. Ann Oncol 2004 ; 15 : 1048-55
91. Lilenbaum RC, Chen CS, Chidiac T et al. : Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2005 ; 16 : 97-101
92. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J : A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated. Lung Cancer 2005 ; 47 : 373-80
93. Pujol JL, Breton JL, Gervais R et al. : Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer : a phase III study addressing the case for cisplatin. Ann Oncol 2005 ; 16 : 602-10
94. Georgoulias V, Ardavanis A, Tsiafaki X et al. : Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer : a phase III randomized trial. J Clin Oncol 2005 ; 23 : 2937-45
95. Tan EH, Szczesna A, Krzakowski M et al. : Randomized study of vinorelbine - gemcitabine versus vinorelbine - carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005 ; 49 : 233-40
96. Katagami N, Takiguchi Y, Yoshimori K et al. : Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma : a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006 ; 1 : 447-53
97. Tan EH, Szczesna A, Krzakowski M et al. : Randomized study of vinorelbine - gemcitabine versus vinorelbine - carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005 ; 49 : 233-40
98. Barlesi F, Pujol JL : Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer : a systematic review of phase III trials. Lung Cancer 2005 ; 49 : 289-98
99. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA : Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer : A Meta-Analysis of the Published Literature. J Clin Oncol 2005 ; 23 : 2926-36
100. Edelman MJ, Clark JI, Chansky K et al. : Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806) : carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 2004 ; 10 : 5022-6
101. Shepherd FA, Dancey J, Ramlau R et al. : Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 ; 18 : 2095-103
102. Fossella FV, DeVore R, Kerr RN et al. : Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [In Process Citation]. J Clin Oncol 2000 ; 18 : 2354-62
103. Esteban E, Gonzalez DS, Fernandez Y et al. : Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003 ; 14 : 1640-7
104. Hanna N, Shepherd FA, Fossella FV et al. : Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 ; 22 : 1589-97
105. Ramlau R, Gervais R, Krzakowski M et al. : Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol 2006 ; 24 : 2800-7
106. Sumpter K, Harper-Wynne C, Yeoh C et al. : Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible ? Lung Cancer 2004 ; 43 : 369-70
107. Mascaux C, Iannino N, Berghmans T, Meert AP, Sculier JP : Le docétaxel comme traitement de rattrapage pour les cancers bronchiques non à petites cellules : étude d'implémentation. Rev Med Brux 2005 ; 26 : 153-8
108. Gervais R, Ducolone A, Breton JL et al. : Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005 ; 16 : 90-6
109. Gridelli C, Gallo C, Di Maio M et al. : A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004 ; 91 : 1996-2004
110. Schuette W, Nagel S, Blankenburg T et al. : Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005 ; 23 : 8389-95
111. Camps C, Massuti B, Jimenez A et al. : Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer : a Spanish Lung Cancer Group trial. Ann Oncol 2006 ; 17 : 467-72
112. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J : A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006 ; 129 : 1031-8
113. 2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 2004 ; 15 : 38-44
114. Barlesi F, Jacot W, Astoul P, Pujol JL : Second-line treatment for advanced non-small cell lung cancer : a systematic review. Lung Cancer 2006 ; 51 : 159-72
115. Giaccone G, Herbst RS, Manegold C et al. : Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial - INTACT 1. J Clin Oncol 2004 ; 22 : 777-84
116. Herbst RS, Giaccone G, Schiller JH et al. : Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial - INTACT 2. J Clin Oncol 2004 ; 22 : 785-94
117. Herbst RS, Prager D, Hermann R et al. : TRIBUTE : a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 5892-9
118. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. : Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-32
119. Thatcher N, Chang A, Parikh P et al. : Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005 ; 366 : 1527-37
120. Tsao MS, Sakurada A, Cutz JC et al. : Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005 ; 353 : 133-44
121. Marchetti A, Felicioni L, Buttitta F : Assessing EGFR mutations. N Engl J Med 2006 ; 354 : 526-8
122. Marchetti A, Martella C, Felicioni L et al. : EGFR mutations in non-small-cell lung cancer : analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005 ; 23 : 857-65
123. Giaccone G, Rodriguez JA : EGFR inhibitors : what have we learned from the treatment of lung cancer ? Nat Clin Pract Oncol 2005 ; 2 : 554-61
124. Inoue A, Suzuki T, Fukuhara T et al. : Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006 ; 24 : 3340-6
125. Paesmans M, Sculier JP, Libert P et al. : Prognostic factors for survival in advanced non-small-cell lung cancer : univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995 ; 13 : 1221-30
126. Paesmans M, Sculier JP, Libert P et al. : Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer : 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997 ; 33 : 2326-32
127. Sculier JP, Paesmans M, Libert P et al. : Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer 1994 ; 30A : 1342-7
128. Robinet G, Thomas P, Breton JL et al. : Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer : Groupe Français de Pneumo- Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001 ; 12 : 59-67
129. Rosen LS, Gordon D, Tchekmedyian S et al. : Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003 ; 21 : 3150-7
130. Rosen LS, Gordon D, Tchekmedyian NS et al. : Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004 ; 100 : 2613-21
131. Van den WT, Huizing MT, Vermorken JB : Bisphosphonates and osteonecrosis of the jaw : cause and effect or a post hoc fallacy ? Ann Oncol 2006 ; 17 : 1197-204
132. Sculier JP, Ghisdal L, Berghmans T et al. : The role of mitomycin in the treatment of non-small cell lung cancer : a systematic review with meta-analysis of the literature. Br J Cancer 2001 ; 84 : 1150-5